HIT Policy Committee gets new members

The Health IT Policy Committee is getting three new members.

Comptroller General Gene L. Dorado made the following three appointments to the committee which makes recommendations to the ONC to develop and adopt a nationwide health information infrastructure:
  • Kathleen Blake, MD, will serve as an expert in healthcare quality measurement and reporting. She currently is vice president for performance improvement at the American Medical Association, executive director for the Physician Consortium for Performance Improvement and an assistant professor of medicine at the Johns Hopkins University School of Medicine in Baltimore.
  • Donna Cryer, JD, will serve as an advocate for patients and consumers. Cryer is founder and president of the Global Liver Institute in Washington, D.C., and also serves on the board of the Society for Participatory Medicine and the Personalized Medicine Coalition and is a member of the National Institutes of Health Learning Health System Stakeholder Advisory Group.
  • Brent Snyder, Esq., will serve as a representative of healthcare providers. Corporate CIO of Altamonte Springs, Fla.-based Adventist Health System, he also is a CHIME member and a fellow of the Healthcare Financial Management Association.
Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.